Abacavir-Lamivudine (Epzicom)

All References

• Anderson AM, Bartlett JA. Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection. Expert Rev Anti Infect Ther. 2005;3:871-83.
  [PubMed Abstract]
• Behrens G, Maserati R, Rieger A, et al. Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles. Antivir Ther. 2012;17:1011-20.
  [PubMed Abstract]
• Brunet L, Moodie EE, Young J, et al. Progression of Liver Fibrosis and Modern Combination Antiretroviral Therapy Regimens in HIV-Hepatitis C-Coinfected Persons. Clin Infect Dis. 2016;62:242-9.
  [PubMed Abstract]
• Campo R, DeJesus E, Bredeek UF, et al. SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen. Clin Infect Dis. 2013;56:1637-45.
  [PubMed Abstract]
• Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. Lancet. 2002;359:733-40.
  [PubMed Abstract]
• Curran A, Rojas J, Cabello A, et al. Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patients. J Antimicrob Chemother. 2016;71:3510-4.
  [PubMed Abstract]
• Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011;154:445-56.
  [PubMed Abstract]
• de los Santos I, Gómez-Berrocal A, Valencia E, et al. Efficacy and tolerability of darunavir/ritonavir in combination with abacavir/lamivudine: an option in selected HIV-infected patients. HIV Clin Trials. 2013;14:254-9.
  [PubMed Abstract]
• DeJesus E, Herrera G, Teofilo E, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis. 2004;39:1038-46.
  [PubMed Abstract]
• Dorjee K, Baxi SM, Reingold AL, Hubbard A. Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study. BMC Infect Dis. 2017;17:708.
  [PubMed Abstract]
• Dorjee K, Choden T, Baxi SM, Steinmaus C, Reingold AL. Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: A systematic review and meta-analyses of results from 17 epidemiologic studies. Int J Antimicrob Agents. 2018;52:541-53.
  [PubMed Abstract]
• Elion R, Berger D, Richmond G, et al. Simplified maintenance therapy with abacavir/lamivudine and atazanavir after discontinuation of ritonavir. HIV Clin Trials. 2010;11:170-3.
  [PubMed Abstract]
• Flandre P, Pugliese P, Allavena C, et al. Comparative risk of failure of ABC/3TC or TDF/FTC based first-line regimens in patients with a high viral load. HIV Med. 2016;17:380-4.
  [PubMed Abstract]
• Grant PM, Tierney C, Budhathoki C, et al. Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202. HIV Clin Trials. 2013;14:284-91.
  [PubMed Abstract]
• Green H, Gibb DM, Walker AS, et al. Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. AIDS. 2007;21:947-55.
  [PubMed Abstract]
• Haskelberg H, Hoy JF, Amin J, et al. Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine. PLoS One. 2012;7:e38377.
  [PubMed Abstract]
• Haskelberg H, Pocock N, Amin J, et al. Hip structural parameters over 96 weeks in HIV-infected adults switching treatment to tenofovir-emtricitabine or abacavir-lamivudine. PLoS One. 2014;9:e94858.
  [PubMed Abstract]
• Lackey P, Mills A, Carpio F, et al. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice. Clin Drug Investig. 2017;37:51-60.
  [PubMed Abstract]
• LePrevost M, Green H, Flynn J, et al. Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children. Pediatr Infect Dis J. 2006;25:533-7.
  [PubMed Abstract]
• Longenecker CT, Kitch D, Sax PE, et al. Reductions in Plasma Cystatin C After Initiation of antiretroviral therapy are associated with reductions in inflammation: ACTG A5224s. J Acquir Immune Defic Syndr. 2015;69:168-77.
  [PubMed Abstract]
• Margot NA, Waters JM, Miller MD. In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine. Antimicrob Agents Chemother. 2006;50:4087-95.
  [PubMed Abstract]
• Martínez E, Arranz JA, Podzamczer D, et al. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. J Acquir Immune Defic Syndr. 2009;51:290-7.
  [PubMed Abstract]
• Martínez E, d'Albuquerque PM, Pérez I, Pich J, Gatell JM. Abacavir/lamivudine versus tenofovir/emtricitabine in virologically suppressed patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS Res Hum Retroviruses. 2013;29:235-41.
  [PubMed Abstract]
• Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis. 2009;49:1591-601.
  [PubMed Abstract]
• McComsey GA, Daar ES, O'Riordan M, et al. Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202. J Infect Dis. 2013;207:604-11.
  [PubMed Abstract]
• McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203:1791-801.
  [PubMed Abstract]
• McComsey GA, Kitch D, Daar ES, et al. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS. 2012;26:1371-85.
  [PubMed Abstract]
• McComsey GA, Kitch D, Sax PE, et al. Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin Infect Dis. 2011;53:185-96.
  [PubMed Abstract]
• Moyle GJ, Dejesus E, Cahn P, et al. Abacavir Once or Twice Daily Combined With Once-Daily Lamivudine and Efavirenz for the Treatment of Antiretroviral-Naive HIV-Infected Adults: Results of the Ziagen Once Daily in Antiretroviral Combination Study. J Acquir Immune Defic Syndr. 2005;38:417-25.
  [PubMed Abstract]
• Moyle GJ, Orkin C, Fisher M, et al. A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individuals. PLoS One. 2015;10:e0116297.
  [PubMed Abstract]
• Moyle GJ, Stellbrink HJ, Compston J, et al. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study. Antivir Ther. 2013;18:905-13.
  [PubMed Abstract]
• Musiime V, Kasirye P, Naidoo-James B, et al. Once vs twice-daily abacavir and lamivudine in African children. AIDS. 2016;30:1761-70.
  [PubMed Abstract]
• Nishijima T, Komatsu H, Teruya K, et al. Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load of more than 100 000  copies/ml. AIDS. 2013;27:839-42.
  [PubMed Abstract]
• Nishijima T, Komatsu H, Teruya K, et al. Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load of more than 100 000 copies/ml. AIDS. 2013;27:839-42.
  [PubMed Abstract]
• Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr. 2010;55:49-57.
  [PubMed Abstract]
• Pulido F, Estrada V, Baril JG, et al. Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks. HIV Clin Trials. 2009;10:76-87.
  [PubMed Abstract]
• Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13:927-35.
  [PubMed Abstract]
• Raffi F, Rachlis A, Brinson C, et al. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials. AIDS. 2015;29:167-74.
  [PubMed Abstract]
• Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381:735-43.
  [PubMed Abstract]
• Rasmussen TA, Jensen D, Tolstrup M, et al. Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial. PLoS One. 2012;7:e32445.
  [PubMed Abstract]
• Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009;361:2230-40.
  [PubMed Abstract]
• Sax PE, Tierney C, Collier AC, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis. 2011;204:1191-201.
  [PubMed Abstract]
• Shlay JC, Sharma S, Peng G, Gibert CL, Grunfeld C. Long-term subcutaneous tissue changes among antiretroviral-naive persons initiating stavudine, zidovudine, or abacavir with lamivudine. J Acquir Immune Defic Syndr. 2008;48:53-62.
  [PubMed Abstract]
• Sivasubramanian G, Frempong-Manso E, Macarthur RD. Abacavir/lamivudine combination in the treatment of HIV: a review. Ther Clin Risk Manag. 2010;6:83-94.
  [PubMed Abstract]
• Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS. 2009;23:1547-56.
  [PubMed Abstract]
• Smith KY, Tierney C, Mollan K, et al. Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine. Clin Infect Dis. 2014;58:555-63.
  [PubMed Abstract]
• Somboonwit C, Kurtyka D, Velez AP. Abacavir and lamivudine combination. Expert Opin Drug Metab Toxicol. 2009;5:1599-606.
  [PubMed Abstract]
• Squires KE, Young B, DeJesus E, et al. ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine. HIV Clin Trials. 2012;13:233-44.
  [PubMed Abstract]
• Squires KE, Young B, DeJesus E, et al. Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients. HIV Clin Trials. 2010;11:69-79.
  [PubMed Abstract]
• Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010;51:963-72.
  [PubMed Abstract]
• Tan DH, Chan K, Raboud J, et al. Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy. J Acquir Immune Defic Syndr. 2011;58:38-46.
  [PubMed Abstract]
• Tebas P, Kumar P, Hicks C, et al. Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks. AIDS. 2015;29:2459-64.
  [PubMed Abstract]
• Trottier B, Machouf N, Thomas R, et al. Abacavir/lamivudine fixed-dose combination with ritonavir-boosted darunavir: a safe and efficacious regimen for HIV therapy. HIV Clin Trials. 2012;13:335-42.
  [PubMed Abstract]
• Vannappagari V, Koram N, Albano J, Tilson H, Gee C. Abacavir and lamivudine exposures during pregnancy and non-defect adverse pregnancy outcomes: data from the antiretroviral pregnancy registry. J Acquir Immune Defic Syndr. 2015;68:359-64.
  [PubMed Abstract]
• Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369:1807-18.
  [PubMed Abstract]
• Wohl DA, Bhatti L, Small CB, et al. Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial. PLoS One. 2014;9:e96187.
  [PubMed Abstract]
• Wohl DA, Bhatti L, Small CB, et al. The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir. HIV Med. 2016;17:106-17.
  [PubMed Abstract]
• Wyatt CM, Kitch D, Gupta SK, et al. Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine. J Acquir Immune Defic Syndr. 2014;67:36-44.
  [PubMed Abstract]
• Young B, Vanig T, Dejesus E, et al. A pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: 48-week results of the SHIELD trial. HIV Clin Trials. 2010;11:260-9.
  [PubMed Abstract]